论文部分内容阅读
为研究血清IL— 3在急性白血病中的动态变化并探讨在白血病治疗过程中如何恰当选用IL— 3。采用酶联免疫吸附试验 (ELISA)方法测定 34例急性白血病患儿血清IL— 3水平 ,1 6例进行动态观察。结果 ,急性白血病患儿ANLL与ALL之间IL— 3水平无明显差异 (P >0 .0 5 )。完全缓解 (CR)后 ,血清IL— 3水平与治疗前比较 ,无显著性差异 (>0 .0 5 )。急性淋巴细胞白血病患儿治疗后高危型 (HR)组比标危型(SR)组血清IL— 3水平明显降低。经治疗CR后 ,有 1 0例IL— 3水平明显升高 ,6例明显降低 ;IL— 3变化与临床分型、获得CR时间及治疗效果有关。结果表明 ,IL— 3与白血病 (AL)治疗有关。建议 :在高危急淋患儿或完全缓解时间 >4周、骨髓衰竭、急性粒细胞白血病患儿应用IL— 3和化疗联合治疗。对缩短完全缓解时间及减少继发耐药 ,缩短骨髓抑制期时间 ,减少感染并发症可能起到重要作用。
To investigate the dynamic changes of serum IL-3 in acute leukemia and to explore how to choose IL-3 properly during leukemia treatment. Serum IL-3 levels were measured in 34 children with acute leukemia by enzyme-linked immunosorbent assay (ELISA), and 16 cases were observed dynamically. Results There was no significant difference in IL-3 level between ANLL and ALL children with acute leukemia (P> 0.05). After complete remission (CR), serum IL-3 levels were not significantly different from those before treatment (> 0.05). Serum IL-3 levels were significantly lower in children with acute lymphoblastic leukemia after high-risk (HR) and standard-risk (SR) treatment. After treatment of CR, 10 cases of IL-3 levels were significantly increased, 6 cases decreased significantly; IL-3 changes and clinical classification, access to CR time and treatment effect. The results show that, IL-3 and leukemia (AL) treatment. Recommendations: In high-risk acute children or complete remission time> 4 weeks, bone marrow failure, acute myeloid leukemia in children with IL-3 and chemotherapy combined treatment. It may play an important role in shortening the time to complete remission, reducing the secondary drug resistance, shortening the time of myelosuppression and reducing the complication of infection.